Center for Reproductive Medicine, Renmin Hospital of Wuhan University, Wuhan 430060, China.
Center for Reproductive Medicine, Renmin Hospital of Wuhan University, Wuhan 430060, China.
Reprod Biomed Online. 2021 Feb;42(2):291-300. doi: 10.1016/j.rbmo.2020.10.006. Epub 2020 Oct 14.
Can luteolysis-targeted drugs, gonadotrophin-releasing hormone antagonist (GnRH-ant), mifepristone and letrozole, administered separately or in combination, prevent the progression of ovarian hyperstimulation syndrome (OHSS) in a rat model?
Thirty-six female Wistar rats were randomly divided into six groups, including control group (OHSS group, ovarian hyperstimulation-induced OHSS); GnRH-ant group (OHSS with GnRH-ant treatment); mifepristone group (OHSS with mifepristone treatment); letrozole group (OHSS with letrozole treatment); combination group (OHSS with GnRH-ant, mifepristone and letrozole treatment in combination). The main outcomes were the alterations in OHSS-related indices, including ovarian weight, vascular permeability, serum oestradiol and progesterone levels, corpus luteum proportion and diameter, ovarian vascular endothelial growth factor (VEGF), interleukin 6 (IL-6), caspase-3 and cleaved caspase-3 levels.
No significant difference was found in body weight gain among the six groups. Compared with the control group, the OHSS group showed significant increases in all OHSS-related indices. GnRH-ant treatment showed decreases in vascular permeability, serum oestradiol level, corpus luteum diameter, ovarian VEGF /IL-6 mRNA levels, and increases in ovarian caspase-3 and cleaved caspase-3 levels. Mifepristone treatment demonstrated reduction in serum progesterone level and corpus luteum diameter, and elevation in ovarian caspase-3 and cleaved caspase-3 levels. Letrozole treatment displayed a decline in serum oestradiol level and corpus luteum diameter, and up-regulation in ovarian caspase-3 and cleaved caspase-3 levels. The combination treatment by GnRH-ant, mifepristone and letrozole showed enhanced synergistic effect on reducing OHSS-related indices.
GnRH-ant, mifepristone and letrozole are beneficial in preventing the progression of OHSS through different luteolytic mechanisms. Cocktail style treatment shows enhanced synergistic effect on preventing the progression of OHSS.
单独或联合使用促黄体溶解靶向药物、促性腺激素释放激素拮抗剂(GnRH-ant)、米非司酮和来曲唑能否预防卵巢过度刺激综合征(OHSS)在大鼠模型中的进展?
36 只雌性 Wistar 大鼠随机分为 6 组,包括对照组(OHSS 组,卵巢过度刺激诱导的 OHSS);GnRH-ant 组(用 GnRH-ant 治疗的 OHSS);米非司酮组(用米非司酮治疗的 OHSS);来曲唑组(用来曲唑治疗的 OHSS);联合组(用 GnRH-ant、米非司酮和来曲唑联合治疗的 OHSS)。主要结局指标为 OHSS 相关指标的变化,包括卵巢重量、血管通透性、血清雌二醇和孕酮水平、黄体比例和直径、卵巢血管内皮生长因子(VEGF)、白细胞介素 6(IL-6)、半胱天冬酶-3 和 cleaved caspase-3 水平。
六组间体重增加无显著差异。与对照组相比,OHSS 组所有 OHSS 相关指标均显著增加。GnRH-ant 治疗可降低血管通透性、血清雌二醇水平、黄体直径、卵巢 VEGF/IL-6mRNA 水平,增加卵巢半胱天冬酶-3 和 cleaved caspase-3 水平。米非司酮治疗可降低血清孕酮水平和黄体直径,增加卵巢半胱天冬酶-3 和 cleaved caspase-3 水平。来曲唑治疗可降低血清雌二醇水平和黄体直径,上调卵巢半胱天冬酶-3 和 cleaved caspase-3 水平。GnRH-ant、米非司酮和来曲唑联合治疗对降低 OHSS 相关指标具有增强的协同作用。
通过不同的黄体溶解机制,GnRH-ant、米非司酮和来曲唑均有助于预防 OHSS 的进展。鸡尾酒式治疗对预防 OHSS 的进展具有增强的协同作用。